Trial result

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

HRR Testing Moves Upfront in Prostate Cancer

A Self-Guided Pathway for Functional Seizures

Enhertu Stumbles in Early Breast Cancer

Endometrial Cancer Gets a Strong ADC Win

Divarasib Raises the KRAS G12C Bar

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

CLL Just Moved a Noncovalent BTK Inhibitor Into First Line

Myeloma Pain May Need 4 Gy, Not a Treatment Odyssey

Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
